(Q53313146)

13 May 2018

title

SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. (English)

1 reference

13 May 2018

1 reference

Gareth Maher-Edwards

1

1 reference

13 May 2018

Ruth Dixon

2

1 reference

13 May 2018

Jackie Hunter

3

1 reference

13 May 2018

Michael Gold

4

1 reference

13 May 2018

Gillian Hopton

5

1 reference

13 May 2018

Gemma Jacobs

6

1 reference

13 May 2018

Jo Hunter

7

1 reference

13 May 2018

Pauline Williams

8

1 reference

13 May 2018

language of work or name

English

0 references

publication date

24 September 2010

1 reference

13 May 2018

International Journal of Geriatric Psychiatry

published in

1 reference

13 May 2018

volume

26

1 reference

13 May 2018

issue

5

1 reference

13 May 2018

page(s)

536-544

1 reference

13 May 2018

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

cites work

1 reference

The selective 5-HT6 receptor antagonists SB-271046 and SB-399885 potentiate NCAM PSA immunolabeling of dentate granule cells, but not neurogenesis, in the hippocampal formation of mature Wistar rats

21 January 2018

1 reference

21 January 2018

1 reference

Polysialic acid-neural cell adhesion molecule in brain plasticity: from synapses to integration of new neurons.

21 January 2018

1 reference

A neuropsychological test battery for use in Alzheimer disease clinical trials.

21 January 2018

1 reference

SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models.

21 January 2018

1 reference

Disease stage in Alzheimer disease and treatment effects of rivastigmine

21 January 2018

1 reference

Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease

21 January 2018

1 reference

5-HT6 receptors: a novel target for cognitive enhancement

21 January 2018

1 reference

Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist

21 January 2018

1 reference

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

21 January 2018

1 reference

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

Donepezil in the treatment of patients with Alzheimer's disease

21 January 2018

1 reference

5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease

21 January 2018

1 reference

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial

21 January 2018

1 reference

Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.

21 January 2018

1 reference

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

7 January 2021

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

1 reference

7 January 2021

Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.

1 reference

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

7 January 2021

Role of 5-HT6 receptors in memory formation

1 reference

7 January 2021

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease

1 reference

7 January 2021

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

1 reference

7 January 2021

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

1 reference

7 January 2021

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

1 reference

7 January 2021

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

1 reference

7 January 2021

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

1 reference

7 January 2021

Identifiers

DOI

10.1002/GPS.2562

1 reference

13 May 2018

PubMed ID

20872778

1 reference

13 May 2018